Literature DB >> 8254097

Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.

G F Watts1, C Castelluccio, C Rice-Evans, N A Taub, H Baum, P J Quinn.   

Abstract

Plasma coenzyme Q (CoQ) was measured in 20 hyperlipidaemic patients treated with diet and simvastatin (an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase); 22 hyperlipidaemic patients treated with diet with alone; and 20 normal controls. Patients treated with simvastatin had a significantly lower plasma CoQ and CoQ: cholesterol ratio than either patients receiving diet alone or normal controls. Use of simvastatin was inversely and independently correlated with both CoQ (p < 0.0001) and CoQ: cholesterol ratio (p < 0.01). There was a significant inverse association between CoQ and dose of simvastatin (p < 0.001). It is concluded that simvastatin may lower the plasma CoQ concentration and this may be greater than the reduction in cholesterol. The possible adverse effect of simvastatin on the metabolism of CoQ may be clinically important and requires further study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254097      PMCID: PMC501696          DOI: 10.1136/jcp.46.11.1055

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  7 in total

1.  Improved high-performance liquid chromatographic method for the determination of coenzyme Q10 in plasma.

Authors:  G Grossi; A M Bargossi; P L Fiorella; S Piazzi; M Battino; G P Bianchi
Journal:  J Chromatogr       Date:  1992-02-28

Review 2.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

Authors:  S M Grundy
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

3.  Lovastatin decreases coenzyme Q levels in humans.

Authors:  K Folkers; P Langsjoen; R Willis; P Richardson; L J Xia; C Q Ye; H Tamagawa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

4.  Lovastatin decreases coenzyme Q levels in rats.

Authors:  R A Willis; K Folkers; J L Tucker; C Q Ye; L J Xia; H Tamagawa
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol.

Authors:  R Stocker; V W Bowry; B Frei
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

6.  Rhabdomyolysis secondary to lovastatin therapy.

Authors:  A A Manoukian; N V Bhagavan; T Hayashi; T A Nestor; C Rios; A G Scottolini
Journal:  Clin Chem       Date:  1990-12       Impact factor: 8.327

7.  Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.

Authors:  P G Elmberger; A Kalén; E Lund; E Reihnér; M Eriksson; L Berglund; B Angelin; G Dallner
Journal:  J Lipid Res       Date:  1991-06       Impact factor: 5.922

  7 in total
  17 in total

1.  Coenzyme Q(10) and statin myalgia: what is the evidence?

Authors:  Emilie Mas; Trevor A Mori
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

Review 2.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial.

Authors:  Heiner K Berthold; Ali Naini; Salvatore Di Mauro; Maarit Hallikainen; Helena Gylling; Wilhelm Krone; Ioanna Gouni-Berthold
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 4.  The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.

Authors:  Iain P Hargreaves; Andrew J Duncan; Simon J R Heales; John M Land
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 5.  Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.

Authors:  Sandra J Hamilton; Gerald F Watts
Journal:  Rev Diabet Stud       Date:  2013-08-10

6.  Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy.

Authors:  Helmut Sinzinger; Fahdi Chehne; Graziana Lupattelli
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  Coenzyme Q10: is there a clinical role and a case for measurement?

Authors:  Sarah L Molyneux; Joanna M Young; Christopher M Florkowski; Michael Lever; Peter M George
Journal:  Clin Biochem Rev       Date:  2008-05

Review 8.  Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 9.  [Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].

Authors:  Markus Zeitlinger; Markus Müller
Journal:  Wien Med Wochenschr       Date:  2003

Review 10.  The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Authors:  Reza Tabrizi; Maryam Akbari; Nasrin Sharifi; Kamran B Lankarani; Mahmood Moosazadeh; Fariba Kolahdooz; Mohsen Taghizadeh; Zatollah Asemi
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.